trial

Cardio Risk of Acute Schizophrenia Olanzapine Duke

NCTId NCT00672464
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by Duke University
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
None
Start
2008-04
Primary completion
2009-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
OlanzapineMetforminSimvastatin

Sponsors

Duke UniversityLead Sponsor

Investigators

1
Joseph P. McEvoy, MDPrincipal Investigator

Sites

2 total
Butner, United StatesDurham, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2009-12
Status
WITHDRAWN
relationships
The graph out of here
drug
Olanzapine
drug
Metformin
drug
Simvastatin
drug
lead_sponsor
Duke University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Joseph P. McEvoy, MD
person